Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.58M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
1.63M
-
Shares change
-
+922K
-
Total reported value, excl. options
-
$454K
-
Value change
-
+$257K
-
Number of buys
-
10
-
Number of sells
-
-2
-
Price
-
$0.28
Significant Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q1 2025
21 filings reported holding CYCC - Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q1 2025.
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.63M shares
.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (1.27M shares), Shay Capital LLC (111K shares), GEODE CAPITAL MANAGEMENT, LLC (62.5K shares), UBS Group AG (62.2K shares), CITADEL ADVISORS LLC (51.9K shares), TWO SIGMA SECURITIES, LLC (16.2K shares), Point72 Asset Management, L.P. (15.3K shares), TWO SIGMA INVESTMENTS, LP (15.3K shares), XTX Topco Ltd (14.3K shares), and Tower Research Capital LLC (TRC) (6.26K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.